Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
| Data | Nome del titolare | Azioni transazionate | Intervallo di valore ($) | Tipo di transazione | Intervallo di prezzo ($) | Azioni a fine dichiarazione | % di variazione |
|---|---|---|---|---|---|---|---|
| 2026-05-07 | Mr. Matthew C. BuschCAO & VP of Finance | -41,00 | 13,58k | Sale to Issuer | 331,11 | 3,15k | -1,29% |
| 2026-05-07 | Mr. Esteban SantosExec. VP of Operations | -522,00 | 172,84k | Sale to Issuer | 331,11 | 75,32k | -0,69% |
| 2026-05-07 | Dr. David M. ReeseExec. VP & CTO | -556,00 | 184,10k | Sale to Issuer | 331,11 | 33,24k | -1,64% |
| 2026-05-07 | Mr. Derek MillerSVP of HR | -151,00 | 50,00k | Sale to Issuer | 331,11 | 9,86k | -1,51% |
| 2026-05-07 | Ms. Rachna KhoslaSVP of Business Development | -93,00 | 30,79k | Sale to Issuer | 331,11 | 6,88k | -1,33% |
| 2026-05-07 | Ms. Nancy A. GrygielSenior VP of Worldwide Compliance & Business Ethics and CCO | -88,00 | 29,14k | Sale to Issuer | 331,11 | 5,96k | -1,46% |
| 2026-05-07 | Mr. Peter H. GriffithExec. VP & CFO | -556,00 | 184,10k | Sale to Issuer | 331,11 | 40,13k | -1,37% |
| 2026-05-07 | Mr. Jonathan P. GrahamExec. VP, General Counsel & Secretary | -499,00 | 165,22k | Sale to Issuer | 331,11 | 31,65k | -1,55% |
| 2026-05-07 | Mr. Murdo GordonEVP of Global Markets & Policy, Medical, Commercial Operations, Government Affairs and Policy | -615,00 | 203,63k | Sale to Issuer | 331,11 | 40,84k | -1,48% |
| 2026-05-07 | Mr. Robert A. BradwayChairman & CEO | -2,08k | 688,38k | Sale to Issuer | 331,11 | 620,48k | -0,33% |
| 2026-05-07 | Dr. James E. BradnerEVP of Research & Development, Artificial Intelligence and Data | -446,00 | 147,68k | Sale to Issuer | 331,11 | 7,10k | -5,91% |
| 2026-05-06 | Dr. James E. BradnerEVP of Research & Development, Artificial Intelligence and Data | -407,00 | 134,14k | Sale to Issuer | 329,59 | 6,60k | -5,81% |
| 2026-05-06 | Mr. Robert A. BradwayChairman & CEO | -1,70k | 560,96k | Sale to Issuer | 329,59 | 618,61k | -0,27% |
| 2026-05-06 | Mr. Matthew C. BuschCAO & VP of Finance | -50,00 | 16,48k | Sale to Issuer | 329,59 | 3,08k | -1,60% |
| 2026-05-06 | Mr. Murdo GordonEVP of Global Markets & Policy, Medical, Commercial Operations, Government Affairs and Policy | -502,00 | 165,45k | Sale to Issuer | 329,59 | 40,29k | -1,23% |
| 2026-05-06 | Mr. Jonathan P. GrahamExec. VP, General Counsel & Secretary | -408,00 | 134,47k | Sale to Issuer | 329,59 | 31,20k | -1,29% |
| 2026-05-06 | Mr. Peter H. GriffithExec. VP & CFO | -502,00 | 165,45k | Sale to Issuer | 329,59 | 39,63k | -1,25% |
| 2026-05-06 | Ms. Nancy A. GrygielSenior VP of Worldwide Compliance & Business Ethics and CCO | -76,00 | 25,05k | Sale to Issuer | 329,59 | 5,88k | -1,28% |
| 2026-05-06 | Ms. Rachna KhoslaSVP of Business Development | -79,00 | 26,04k | Sale to Issuer | 329,59 | 6,80k | -1,15% |
| 2026-05-06 | Mr. Derek MillerSVP of HR | -123,00 | 40,54k | Sale to Issuer | 329,59 | 9,72k | -1,25% |
| 2026-05-06 | Dr. David M. ReeseExec. VP & CTO | -454,00 | 149,63k | Sale to Issuer | 329,59 | 32,75k | -1,37% |
| 2026-05-06 | Mr. Esteban SantosExec. VP of Operations | -427,00 | 140,73k | Sale to Issuer | 329,59 | 74,85k | -0,57% |
| 2026-05-02 | Mr. Esteban SantosExec. VP of Operations | -1,34k | 441,30k | Sale to Issuer | 329,82 | 74,44k | -1,77% |
| 2026-05-02 | Dr. David M. ReeseExec. VP & CTO | -1,43k | 472,63k | Sale to Issuer | 329,82 | 32,31k | -4,25% |
| 2026-05-02 | Mr. Derek MillerSVP of HR | -365,00 | 120,38k | Sale to Issuer | 329,82 | 9,61k | -3,66% |
| 2026-05-02 | Ms. Rachna KhoslaSVP of Business Development | -225,00 | 74,21k | Sale to Issuer | 329,82 | 6,72k | -3,24% |
| 2026-05-04 | Ms. Nancy A. GrygielSenior VP of Worldwide Compliance & Business Ethics and CCO | -1,24k | 400,45k | Vendita | 323,73 | 5,81k | -17,56% |
| 2026-05-02 | Ms. Nancy A. GrygielSenior VP of Worldwide Compliance & Business Ethics and CCO | -242,00 | 79,82k | Sale to Issuer | 329,82 | 5,81k | -4,00% |
| 2026-05-02 | Mr. Peter H. GriffithExec. VP & CFO | -1,43k | 472,63k | Sale to Issuer | 329,82 | 39,16k | -3,53% |
| 2026-05-02 | Mr. Jonathan P. GrahamExec. VP, General Counsel & Secretary | -1,26k | 414,58k | Sale to Issuer | 329,82 | 30,81k | -3,92% |
| 2026-05-02 | Mr. Murdo GordonEVP of Global Markets & Policy, Medical, Commercial Operations, Government Affairs and Policy | -1,59k | 525,40k | Sale to Issuer | 329,82 | 39,81k | -3,85% |
| 2026-05-02 | Mr. Matthew C. BuschCAO & VP of Finance | -68,00 | 22,43k | Sale to Issuer | 329,82 | 2,99k | -2,22% |
| 2026-05-02 | Mr. Robert A. BradwayChairman & CEO | -5,06k | 1,67M | Sale to Issuer | 329,82 | 616,98k | -0,81% |
| 2026-03-16 | Mr. Esteban SantosExec. VP of Operations | -5,62k | 2,06M | Sale to Issuer | 366,21 | 73,37k | -7,12% |
| 2026-03-16 | Dr. David M. ReeseExec. VP & CTO | -6,02k | 2,21M | Sale to Issuer | 366,21 | 31,16k | -16,20% |
| 2026-03-16 | Mr. Derek MillerSVP of HR | -1,62k | 591,80k | Sale to Issuer | 366,21 | 9,31k | -14,78% |
| 2026-03-16 | Ms. Rachna KhoslaSVP of Business Development | -707,00 | 258,91k | Sale to Issuer | 366,21 | 6,54k | -9,75% |
| 2026-03-16 | Ms. Nancy A. GrygielSenior VP of Worldwide Compliance & Business Ethics and CCO | -787,00 | 288,21k | Sale to Issuer | 366,21 | 6,86k | -10,29% |
| 2026-03-16 | Mr. Peter H. GriffithExec. VP & CFO | -5,75k | 2,10M | Sale to Issuer | 366,21 | 38,01k | -13,14% |
| 2026-03-16 | Mr. Jonathan P. GrahamExec. VP, General Counsel & Secretary | -5,35k | 1,96M | Sale to Issuer | 366,21 | 29,80k | -15,23% |
| 2026-03-16 | Mr. Murdo GordonEVP of Global Markets & Policy, Medical, Commercial Operations, Government Affairs and Policy | -6,69k | 2,45M | Sale to Issuer | 366,21 | 38,53k | -14,80% |
| 2026-03-16 | Mr. Robert A. BradwayChairman & CEO | -21,29k | 7,80M | Sale to Issuer | 366,21 | 612,90k | -3,36% |
| 2026-03-16 | Mr. Matthew C. BuschCAO & VP of Finance | -327,00 | 119,75k | Sale to Issuer | 366,21 | 2,89k | -10,17% |
| 2026-03-04 | Mr. Robert A. BradwayChairman & CEO | 35,50k | 5,55M | Derivative Exercise and Retained Stock | 156,35 | 633,62k | 5,93% |
| 2026-03-04 | Mr. Robert A. BradwayChairman & CEO | -84,29k | 18,79M | Derivative Exercise and Sale | 156,35 - 379,27 | 633,62k | - |
| 2026-02-26 | Mr. Esteban SantosExec. VP of Operations | -54,79k | 11,50M | Derivative Exercise and Sale | 162,60 - 379,12 | 68,16k | - |
| 2026-02-19 | Mr. Matthew C. BuschCAO & VP of Finance | -1.000,00 | 375,79k | Vendita | 375,79 | 2,26k | -30,64% |
| 2026-02-09 | Dr. James E. BradnerEVP of Research & Development, Artificial Intelligence and Data | -3,10k | 1,19M | Sale to Issuer | 384,32 | 15,21k | -16,95% |
| 2025-11-20 | Ms. Nancy A. GrygielSenior VP of Worldwide Compliance & Business Ethics and CCO | -3,14k | 525,98k | Derivative Exercise and Sale | 162,60 - 337,26 | 5,59k | - |
| 2025-11-12 | Ms. Rachna KhoslaSVP of Business Development | -890,00 | 299,26k | Vendita | 336,24 | 5,04k | -15,02% |
| 2025-11-12 | Mr. Murdo GordonEVP of Global Markets & Policy, Medical, Commercial Operations, Government Affairs and Policy | -6,88k | 2,32M | Vendita | 336,83 | 29,52k | -18,90% |
| 2025-11-11 | Dr. David M. ReeseExec. VP & CTO | -6,80k | 0,00 | Other Disposition | - | 23,90k | -22,15% |
| 2025-11-05 | Ms. Rachna KhoslaSVP of Business Development | -226,00 | 67,05k | Sale to Issuer | 296,70 | 6,02k | -3,62% |
| 2025-11-05 | Mr. Matthew C. BuschCAO & VP of Finance | -202,00 | 59,93k | Sale to Issuer | 296,70 | 3,11k | -6,10% |
| 2025-08-20 | Ms. Nancy A. GrygielSenior VP of Worldwide Compliance & Business Ethics and CCO | -1,27k | 376,28k | Vendita | 296,99 | 5,58k | -18,51% |
| 2025-06-05 | Ms. Rachna KhoslaSVP of Business Development | -1,50k | 434,52k | Vendita | 289,68 | 5,91k | -20,25% |
Le azioni che visualizzerai appariranno in questo riquadro, così potrai facilmente tornare alle quotazioni di tuo interesse.
Assistenza: support@advfn.it
Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni
Registrati con e-mail
Hai già un account? Accedi
Non hai un account? Registrati
Registrandomi, confermo di aver letto, capito, e accetto i termini e condizioni ADVFN e che sono un investitore privato.
Caratteristiche principali
Premium
